Cargando…
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
OBJECTIVES: To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. METHODS: In the SWEFOT trial population, disease modifying antirheumatic drug (DMARD) naïve RA patients started methotrexate; 3-month responders (DAS28 <3.2) continued (...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515990/ https://www.ncbi.nlm.nih.gov/pubmed/24706006 http://dx.doi.org/10.1136/annrheumdis-2013-204601 |
_version_ | 1782382999684251648 |
---|---|
author | Saevarsdottir, Saedis Rezaei, Hamed Geborek, Pierre Petersson, Ingemar Ernestam, Sofia Albertsson, Kristina Forslind, Kristina van Vollenhoven, Ronald F |
author_facet | Saevarsdottir, Saedis Rezaei, Hamed Geborek, Pierre Petersson, Ingemar Ernestam, Sofia Albertsson, Kristina Forslind, Kristina van Vollenhoven, Ronald F |
author_sort | Saevarsdottir, Saedis |
collection | PubMed |
description | OBJECTIVES: To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. METHODS: In the SWEFOT trial population, disease modifying antirheumatic drug (DMARD) naïve RA patients started methotrexate; 3-month responders (DAS28 <3.2) continued (n=147), while non-responders were randomised to addition of sulfasalazine+hydroxychloroquine (n=130) or infliximab (n=128). X-rays were scored by the Sharp-van der Hejde score (SHS) method and radiographic progression was defined as a ≥5 increase after 1 year. Potential baseline predictors of radiographic progression were tested using multivariable logistic regression, adjusted for potential confounders. RESULTS: 79 of 311 patients with available radiographs at baseline and follow-up had radiographic progression. The following baseline parameters were independent predictors of radiographic progression at 1 year: baseline erosions (adjusted OR=2.29, 95% CI 1.24 to 4.24), erythrocyte sedimentation rate (adjusted OR per tertile increase=1.72, 95% CI 1.12 to 2.65) and C-reactive protein (adjusted OR per tertile increase=1.52, 95% CI 1.03 to 2.26). Current smoking was an independent predictor of radiographic progression (adjusted OR=2.17, 95% CI 1.06 to 4.45). These results remained after further adjustment for treatment strategy. Three-dimensional matrix including current smoking status, erosions and C-reactive protein tertiles showed a 12–63% risk gradient from patients carrying none compared with all predictors. Rheumatoid factor (RF)/anti-cyclic citrullinated peptide (anti-CCP) positivity did not significantly predict radiographic progression using SHS increase ≥5 as cut-off. In a secondary exploratory analysis using cut-off >1, both RF and anti-CCP positivity were significant predictors in the unadjusted, but not the adjusted analyses. The other parameters also remained significant using this lower cut-off. CONCLUSIONS: In addition to previously described predictors, we identified smoking as a strong independent risk factor for radiographic progression in early RA. TRIAL REGISTRATION NUMBER: NCT00764725. |
format | Online Article Text |
id | pubmed-4515990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45159902015-08-03 Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial Saevarsdottir, Saedis Rezaei, Hamed Geborek, Pierre Petersson, Ingemar Ernestam, Sofia Albertsson, Kristina Forslind, Kristina van Vollenhoven, Ronald F Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVES: To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. METHODS: In the SWEFOT trial population, disease modifying antirheumatic drug (DMARD) naïve RA patients started methotrexate; 3-month responders (DAS28 <3.2) continued (n=147), while non-responders were randomised to addition of sulfasalazine+hydroxychloroquine (n=130) or infliximab (n=128). X-rays were scored by the Sharp-van der Hejde score (SHS) method and radiographic progression was defined as a ≥5 increase after 1 year. Potential baseline predictors of radiographic progression were tested using multivariable logistic regression, adjusted for potential confounders. RESULTS: 79 of 311 patients with available radiographs at baseline and follow-up had radiographic progression. The following baseline parameters were independent predictors of radiographic progression at 1 year: baseline erosions (adjusted OR=2.29, 95% CI 1.24 to 4.24), erythrocyte sedimentation rate (adjusted OR per tertile increase=1.72, 95% CI 1.12 to 2.65) and C-reactive protein (adjusted OR per tertile increase=1.52, 95% CI 1.03 to 2.26). Current smoking was an independent predictor of radiographic progression (adjusted OR=2.17, 95% CI 1.06 to 4.45). These results remained after further adjustment for treatment strategy. Three-dimensional matrix including current smoking status, erosions and C-reactive protein tertiles showed a 12–63% risk gradient from patients carrying none compared with all predictors. Rheumatoid factor (RF)/anti-cyclic citrullinated peptide (anti-CCP) positivity did not significantly predict radiographic progression using SHS increase ≥5 as cut-off. In a secondary exploratory analysis using cut-off >1, both RF and anti-CCP positivity were significant predictors in the unadjusted, but not the adjusted analyses. The other parameters also remained significant using this lower cut-off. CONCLUSIONS: In addition to previously described predictors, we identified smoking as a strong independent risk factor for radiographic progression in early RA. TRIAL REGISTRATION NUMBER: NCT00764725. BMJ Publishing Group 2015-08 2014-04-04 /pmc/articles/PMC4515990/ /pubmed/24706006 http://dx.doi.org/10.1136/annrheumdis-2013-204601 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Clinical and Epidemiological Research Saevarsdottir, Saedis Rezaei, Hamed Geborek, Pierre Petersson, Ingemar Ernestam, Sofia Albertsson, Kristina Forslind, Kristina van Vollenhoven, Ronald F Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial |
title | Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial |
title_full | Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial |
title_fullStr | Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial |
title_full_unstemmed | Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial |
title_short | Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial |
title_sort | current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the swefot trial |
topic | Clinical and Epidemiological Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515990/ https://www.ncbi.nlm.nih.gov/pubmed/24706006 http://dx.doi.org/10.1136/annrheumdis-2013-204601 |
work_keys_str_mv | AT saevarsdottirsaedis currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial AT rezaeihamed currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial AT geborekpierre currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial AT peterssoningemar currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial AT ernestamsofia currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial AT albertssonkristina currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial AT forslindkristina currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial AT vanvollenhovenronaldf currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial |